Table 4.

Reasons to discontinue TNFi treatment per treatment group. All data are percentages.

Reasons to Discontinue TNFiMonotherapy 181/320SSZ 48/103LEF 46/80Other csDMARD 42/99MTX Alone 347/919MTX+ csDMARD 159/412
Side effects42.951.454.548.843.445.6
Ineffectiveness50.648.643.246.350.652.4
Ineffectiveness and side effects6.50.02.34.96.02.0
  • TNFi: tumor necrosis factor inhibitor; MTX: methotrexate; SSZ: sulfasalazine; LEF: leflunomide; csDMARD: conventional synthetic disease-modifying antirheumatic drugs.